Refine
Has Fulltext
- yes (35)
Is part of the Bibliography
- yes (35) (remove)
Year of publication
- 2016 (35) (remove)
Document Type
- Journal article (35) (remove)
Language
- English (35) (remove)
Keywords
- Aspergillus fumigatus (2)
- Bone-marrow-transplantation (2)
- chemotherapy (2)
- multiple myeloma (2)
- 177Lu (1)
- AIDS (1)
- Acute lymphocytic leukaemia (1)
- Alpha therapy (1)
- Autoimmune diseases (1)
- Bacteria (1)
- Bone marrow transplantantation (1)
- Breath tests (1)
- CA19-9 (1)
- CD11b+ myeloid cells (1)
- Cancer genetics (1)
- Candida albicans (1)
- Central nervous system (1)
- Central nervous system infection (1)
- Clinical practice guidelines (1)
- Clinical remission (1)
- Cytokine receptors (1)
- Diagnosis (1)
- Drug development (1)
- Drug metabolism (1)
- Drug-free remission (1)
- Duchenne muscular dystrophy (1)
- Expression (1)
- FOLFIRI (1)
- FOLFOX (1)
- Factor receptor (1)
- Fungal (1)
- Genetics research (1)
- Glucose metabolism (1)
- Graft versus Tumor (1)
- Graft-versus-leukemia (1)
- Guideline (1)
- Guinea pig model (1)
- HIV (1)
- HIV infections (1)
- Hepatitis B virus (1)
- Hepatitis C (1)
- Herpes simplex encephalitis (1)
- Herpes simplex virus (1)
- Hsp90 (1)
- Human immunodefiency virus (1)
- IL-12 family (1)
- Imatinib (1)
- Immunocompromised patient (1)
- Infections (1)
- Inflammation (1)
- Influenzae type B (1)
- Intracellular domain (1)
- Invasive Aspergillosis (1)
- Invasive fungal-infections (1)
- Jak kinases (1)
- Lipid metabolism (1)
- Liposomal amphotericin-B (1)
- Liver cirrhosis (1)
- Low-dose acyclovir (1)
- MAG3 (1)
- MPACT (1)
- Malignant melanoma (1)
- NFkB-relatedgenes (1)
- PRRT (1)
- Pneumocystis-carinii-pneumonia (1)
- Polymerase chain raction (1)
- Progressive multifocal leukoencephalopathy (1)
- Real-time PCR (1)
- Regulatory-cells (1)
- Respiratory syncytial virus (1)
- Responses (1)
- Rheumatoid arthritis (1)
- STAT3 activation (1)
- Signal transduction (1)
- Skin cancer screening (1)
- Stage distribution (1)
- Suppression (1)
- Survival analysis (1)
- Synovitis (1)
- T-cells (1)
- TNM staging (1)
- Th17 (1)
- Transport (1)
- Treatment (1)
- Tregs (1)
- Tumor-necrosis-factor (1)
- Tyrosine phosphorylation (1)
- Validation (1)
- Varicella-Zoster-Virus (1)
- Varicella-zoster-virus (1)
- Viral (1)
- acute Graft versus Host Disease (1)
- adenocarcinoma of the ampulla of Vater (1)
- adjuvant (1)
- allogeneic stem cell transplantation (1)
- alternative to animal testing (1)
- amphotericin B (1)
- amplicon sequencing (1)
- anaplastic medulloblastoma (1)
- anastomotic leakage (1)
- anemia (1)
- animal model (1)
- antiviral treatment (1)
- aspergillus fumigatus (1)
- beta-D-glucan (1)
- biliary-tract cancer (1)
- biomarkers Myelomas (1)
- blood flow (1)
- bone imaging (1)
- brain tumor (1)
- cancer stem cells (1)
- care (1)
- children (1)
- chronic myelogenous leukemia (1)
- clinical-practice (1)
- collagens (1)
- complication (1)
- corticosteroids and cyclophosphamide (1)
- daratumumab monotherapy (1)
- discordance (1)
- disease-activity score (1)
- drug adherence (1)
- endosponge (1)
- epithelial-mesenchymal transition (1)
- european leukemia net (1)
- fatigue (1)
- fatty liver (1)
- fine-needle-aspiration (1)
- fluorescence microscopy (1)
- fluorescent dyes (1)
- fungal disease (1)
- fungal host response (1)
- fungal infection (1)
- galactomannan (1)
- gastric cancer (1)
- gastrointestinal dysfunction (1)
- gemcitabine (1)
- gene expression data (1)
- gene regulation in immune cells (1)
- genetic polymorphisms (1)
- group 3 (1)
- growth-factor-receptor (1)
- health-assessment questionnaire (1)
- hematopoietic SCT (1)
- hepatic stellate cells (1)
- high-risk hematology (1)
- highly-active antiretroviral therapy (1)
- human biomarker (1)
- human cholangiocellular carcinoma (1)
- human intrahepatic cholangiocarcinoma (1)
- immune activation (1)
- immune cell recruitment (1)
- induce cyclooxygenase-2 expression (1)
- insulin (1)
- insulin signaling (1)
- integrins (1)
- interaction (1)
- interferon alpha (IFNα) (1)
- interferon alpha signalling (1)
- interferon-alpha (1)
- intestinal-type adenocarcinoma (1)
- invasive aspergillosis (1)
- invasive fungal infections (1)
- ischemic stroke (1)
- leukemia (1)
- mammalian genomics (1)
- melanoma therapy (1)
- methylation (1)
- micronuclei (1)
- minimally important difference (1)
- molecular response in cml (1)
- mouse models DNA damage (1)
- multimodal (1)
- multiple myeloma Lesions (1)
- myeloma cells (1)
- nab-paclitaxel (1)
- nanoparticle albumin-bound paclitaxel (1)
- neoadjuvant (1)
- neuroendocrine tumor (1)
- nucleoside transporter (1)
- oncology (1)
- orthotopic xenograft (1)
- oxidative stress (1)
- pancreatic cancer (1)
- pancreatobiliary type (1)
- panobinostat (1)
- physicians (1)
- platelet activation (1)
- platelet aggregation (1)
- platelets (1)
- primary sclerosing cholangitis (1)
- pulmonary aspergillosis (1)
- rare SNP (1)
- real-time PCR (1)
- receptor tyrosine kinases (1)
- relapsed (1)
- relapsed and refractory (1)
- renal scintigraphy (1)
- reported outcomes (1)
- ribavirin serum levels (1)
- risk factor (1)
- serotonin (1)
- skin equivalents (1)
- suppression (1)
- survival (1)
- susceptibility (1)
- systemic sclerosis (1)
- tissue engineering (1)
- transporter protein associated with antigen processing-1 (TAP1) (1)
- validation (1)
- vascularization (1)
- viral load (1)
- viral replication (1)
Institute
- Medizinische Klinik und Poliklinik II (35) (remove)
Background
Serotonin (5-hydroxytryptamin, 5-HT) is an indolamine platelet agonist, biochemically derived from tryptophan. 5-HT is secreted from the enterochromaffin cells into the gastrointestinal tract and blood. Blood 5-HT has been proposed to regulate hemostasis by acting as a vasoconstrictor and by triggering platelet signaling through 5-HT receptor 2A (5HTR2A). Although platelets do not synthetize 5-HT, they take 5-HT up from the blood and store it in their dense granules which are secreted upon platelet activation.
Objective
To identify the molecular composite of the 5-HT uptake system in platelets and elucidate the role of platelet released 5-HT in thrombosis and ischemic stroke. Methods: 5-HT transporter knockout mice (5Htt\(^{-/-}\)) were analyzed in different in vitro and in vivo assays and in a model of ischemic stroke.
Results
In 5Htt\(^{-/-}\) platelets, 5-HT uptake from the blood was completely abolished and agonist-induced Ca2+ influx through store operated Ca\(^{2+}\) entry (SOCE), integrin activation, degranulation and aggregation responses to glycoprotein VI (GPVI) and C-type lectin-like receptor 2 (CLEC-2) were reduced. These observed in vitro defects in 5Htt\(^{-/-}\) platelets could be normalized by the addition of exogenous 5-HT. Moreover, reduced 5-HT levels in the plasma, an increased bleeding time and the formation of unstable thrombi were observed ex vivo under flow and in vivo in the abdominal aorta and carotid artery of 5Htt\(^{-/-}\) mice. Surprisingly, in the transient middle cerebral artery occlusion (tMCAO) model of ischemic stroke 5Htt\(^{-/-}\) mice showed nearly normal infarct volume and the neurological outcome was comparable to control mice.
Conclusion
Although secreted platelet 5-HT does not appear to play a crucial role in the development of reperfusion injury after stroke, it is essential to amplify the second phase of platelet activation through SOCE and plays an important role in thrombus stabilization.
Comparison of nonculture blood-based tests for diagnosing invasive aspergillosis in an animal model
(2016)
The European Aspergillus PCR Initiative (EAPCRI) has provided recommendations for the PCR testing of whole blood (WB) and serum/plasma. It is important to test these recommended protocols on nonsimulated "in vivo" specimens before full clinical evaluation. The testing of an animal model of invasive aspergillosis (IA) overcomes the low incidence of disease and provides experimental design and control that is not possible in the clinical setting. Inadequate performance of the recommended protocols at this stage would require reassessment of methods before clinical trials are performed and utility assessed. The manuscript describes the performance of EAPCRI protocols in an animal model of invasive aspergillosis. Blood samples taken from a guinea pig model of IA were used for WB and serum PCR. Galactomannan and beta-D-glucan detection were evaluated, with particular focus on the timing of positivity and on the interpretation of combination testing. The overall sensitivities for WB PCR, serum PCR, galactomannan, and beta-D-glucan were 73%, 65%, 68%, and 46%, respectively. The corresponding specificities were 92%, 79%, 80%, and 100%, respectively. PCR provided the earliest indicator of IA, and increasing galactomannan and beta-D-glucan values were indicators of disease progression. The combination of WB PCR with galactomannan and beta-D-glucan proved optimal (area under the curve AUC], 0.95), and IA was confidently diagnosed or excluded. The EAPRCI-recommended PCR protocols provide performance comparable to commercial antigen tests, and clinical trials are warranted. By combining multiple tests, IA can be excluded or confirmed, highlighting the need for a combined diagnostic strategy. However, this approach must be balanced against the practicality and cost of using multiple tests.
Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of \(^{99m}\)Tc-mercaptoacetyltriglycine (\(^{99m}\)Tc-MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was measured prior to 128 PRRT cycles (7.6±0.4 GBq \(^{177}\)Lu-octreotate/octreotide each) in 32 patients. TER reduction during PRRT was corrected for age-related decrease and analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate (GFR) as measure for renal function was derived from serum creatinine. The mean TER was 234 ± 53 ml/min/1.73 m² before PRRT (baseline) and 221 ± 45 ml/min/1.73 m² after a median follow-up of 370 days. The age-corrected decrease (mean: -3%, range: -27% to +19%) did not reach significance (p=0.09) but significantly correlated with the baseline TER (Spearman p=-0.62, p<0.001). Patients with low baseline TER showed an improved TER after PRRT, high decreases were only observed in individuals with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatinine-derived GFR estimates in predicting late nephropathy. TER assessed by \(^{99m}\)Tc-MAG3clearance prior to and during PRRT is not suitable as early predictor of renal injury and an increased risk for late nephropathy.
Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations. This is the updated version of the AGHIO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria.
A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9;11)(p21∼22;q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with 4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9;11)(p21∼22;q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype.
Background
Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients.
Methods
Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival.
Results
The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97–0.97), sex (OR 1.18, 95% CI 1.11–1.25), date of diagnosis (OR 1.05, 95% CI 1.04–1.06), ‘diagnosis during screening’ (OR 3.24, 95% CI 2.50–4.19) and place of residence (OR 1.23, 95% CI 1.16–1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8–83.9%).
Conclusions
No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.
"
Infections of the central nervous system (CNS) are infrequently diagnosed in immunocompetent patients, but they do occur in a significant proportion of patients with hematological disorders. In particular, patients undergoing allogeneic hematopoietic stem-cell transplantation carry a high risk for CNS infections of up to 15%. Fungi and Toxoplasma gondii are the predominant causative agents. The diagnosis of CNS infections is based on neuroimaging, cerebrospinal fluid examination and biopsy of suspicious lesions in selected patients. However, identification of CNS infections in immunocompromised patients could represent a major challenge since metabolic disturbances, side-effects of antineoplastic or immunosuppressive drugs and CNS involvement of the underlying hematological disorder may mimic symptoms of a CNS infection. The prognosis of CNS infections is generally poor in these patients, albeit the introduction of novel substances (e.g. voriconazole) has improved the outcome in distinct patient subgroups. This guideline has been developed by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) with the contribution of a panel of 14 experts certified in internal medicine, hematology/oncology, infectious diseases, intensive care, neurology and neuroradiology. Grades of recommendation and levels of evidence were categorized by using novel criteria, as recently published by the European Society of Clinical Microbiology and Infectious Diseases.
Objective
To use statistical methods to establish a threshold for individual response in patient-reported outcomes (PROs) in patients with rheumatoid arthritis.
Methods
We used an analysis of variance model in patients on stable therapy (discovery cohort) to establish critical differences (d(crit)) for the minimum change associated with a significant individual patient response (beyond normal variation) in the PRO measures of pain (0-10), fatigue (0-10), and function (Funktionsfragebogen Hannover questionnaire; 0-100). We then evaluated PRO responses in patients initiating adalimumab in a noninterventional study (treatment cohort).
Results
In the discovery cohort (n=700), PROs showed excellent long-term retest reliability. The minimum change that exceeded random fluctuation was conservatively determined to be 3 points for pain, 4 points for fatigue, and 16 points for function. In the treatment cohort (n=2,788), 1,483 patients (53.2%) achieved a significant individual therapeutic response as assessed by Disease Activity Score in 28 joints (DAS28)-d(crit) (1.8 points) after 12 months of adalimumab treatment; 68.5% of patients with a DAS28-d(crit) response achieved a significant improvement in pain, whereas approximately 40% achieved significant improvements in fatigue or function. Significant improvements in all 3 PROs occurred in 22.7% of patients; 22.8% did not have any significant PRO responses. In contrast, significant improvements in all 3 PROs occurred in only 4.4% of 1,305 patients who did not achieve a DAS28-d(crit) response at month 12, and 59.1% did not achieve any significant PRO responses.
Conclusion
The establishment of critical differences in PROs distinguishes true responses from random variation and provides insights into appropriate patient management.
Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway. In August 2015, the European Commission authorized panobinostat for use in combination with bortezomib and dexamethasone for the treatment of relapsed or relapsed and refractory multiple myeloma (MM) in patients who have received aeyen2 prior regimens including bortezomib and an immunomodulatory drug. In January 2016, the National Institute for Health and Care Excellence recommended panobinostat for use in the same combination and patient population. The authorization and recommendation were based on results from the pivotal phase 3 PANORAMA 1 (NCT01023308) clinical trial, which demonstrated an improvement in median progression-free survival of 7.8 months for the three-drug combination compared with placebo plus bortezomib and dexamethasone in this patient population. This review will discuss the current treatment landscape for relapsed/refractory MM, the mechanism of action of panobinostat, clinical data supporting the European authorization, concerns about safety and strategies for mitigating toxicity, and how panobinostat fits into the current MM landscape in Europe.
Objective
To analyse the role of multibiomarker disease activity (MBDA) score in predicting disease relapses in patients with rheumatoid arthritis (RA) in sustained remission who tapered disease modifying antirheumatic drug (DMARD) therapy in RETRO, a prospective randomised controlled trial.
Methods
MBDA scores (scale 1-100) were determined based on 12 inflammation markers in baseline serum samples from 94 patients of the RETRO study. MBDA scores were compared between patients relapsing or remaining in remission when tapering DMARDs. Demographic and disease-specific parameters were included in multivariate logistic regression analysis for defining predictors of relapse.
Results
Moderate-to-high MBDA scores were found in 33% of patients with RA overall. Twice as many patients who relapsed (58%) had moderate/high MBDA compared with patients who remained in remission (21%). Baseline MBDA scores were significantly higher in patients with RA who were relapsing than those remaining in stable remission (N=94; p=0.0001) and those tapering/stopping (N=59; p=0.0001). Multivariate regression analysis identified MBDA scores as independent predictor for relapses in addition to anticitrullinated protein antibody (ACPA) status. Relapse rates were low (13%) in patients who were MBDA-/ACPA-, moderate in patients who were MBDA+/ACPA- (33.3%) and MBDA-ACPA+ (31.8%) and high in patients who were MBDA+/ACPA+ (76.4%).
Conclusions
MBDA improved the prediction of relapses in patients with RA in stable remission undergoing DMARD tapering. If combined with ACPA testing, MBDA allowed prediction of relapse in more than 80% of the patients.
Trial registration number EudraCT
2009-015740-42.